Rasheed Singleton, MD
Interventional Pain Medicine · Conyers, GANPI 1316924558
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Kaleo, Inc. accounts for 69.5% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2019 at $10,228 and has fallen 97.3% since, to $279 in 2025.
Across 193 payments — averaging $71.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kaleo, Inc.$10K
- Boston Scientific$1K
- Nevro Corp.$663
- Collegium Pharmaceutical, Inc.$363
- AbbVie$332
- Medtronic$246
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$7,00051%
- Travel & lodging$2,40917%
- Food & beverage$4,41232%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kaleo, Inc. | 20 | $9,626 |
| Boston Scientific | 23 | $1,081 |
| Nevro Corp. | 16 | $663 |
| Collegium Pharmaceutical, Inc. | 27 | $363 |
| AbbVie(2 entities) | 22 | $332 |
| Medtronic | 8 | $246 |
| Pfizer | 13 | $204 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $190 |
| Globus Medical | 2 | $177 |
| IBSA Pharma Inc. | 8 | $140 |
| Abbott | 5 | $116 |
| Amgen | 4 | $95 |
| Lundbeck LLC | 2 | $93 |
| Tersera Therapeutics LLC | 3 | $63 |
| Arbor Pharmaceuticals, Inc. | 3 | $55 |
| Fidia Pharma USA Inc. | 2 | $42 |
| Novartis | 3 | $36 |
| Eisai Inc. | 2 | $36 |
| Stimwave Technologies Incorporated | 2 | $30 |
| AstraZeneca | 2 | $30 |
| Sentynl Therapeutics, Inc. | 2 | $28 |
| Avanos Medical | 1 | $27 |
| Averitas Pharma Inc. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| SPR Therapeutics, Inc | 1 | $18 |
| Johnson & Johnson | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Bioventus LLC | 1 | $16 |
| Shionogi Inc | 1 | $15 |
| Curonix LLC | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $12 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,854 in reported general payments places this provider in the 80th percentile of 129 interventional pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 54 | $37,078 |
| BelbucaBuprenorphine Hcl | 32 | $28,078 |
| Nucynta ErTapentadol Hcl | 21 | $26,366 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 396 | $11,745 |
| Buprenorphine | 35 | $9,910 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 339 | $7,756 |
| Tramadol Hcl ErTramadol Hcl | 45 | $3,144 |
| Morphine Sulfate ErMorphine Sulfate | 111 | $3,035 |
| Oxycodone Hcl | 168 | $2,772 |
| Pregabalin | 134 | $2,190 |
| Gabapentin | 131 | $1,466 |
| Naloxone Hcl | 21 | $1,387 |
| Tramadol Hcl | 138 | $935 |
| Tizanidine Hcl | 76 | $811 |
| Morphine Sulfate | 13 | $376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta Er | $363 | $91,521107 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $21 | $10,28648 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 129 interventional pain medicine providers in Georgia.
Other interventional pain medicine in Conyers
- David NeckmanConyers$9K
- Emmanuel GageBrunswick$602K
- Jordan TateJasper$540K
- Christopher BovinetBrunswick$338K
- David RosenfeldCovington$249K
- Nathan NeufeldNewnan$171K
- Ryan BudwanyLawrenceville$123K
- Alexandra MoreiraAtlanta$79K
- Sushanth BodaNewnan$55K
- Christopher AndrianoStockbridge$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.